ReAlta Drug Shows Promise in Protecting Newborn Brains from Oxygen Deprivation Injuries
By Daniella Parra ReAlta Life Sciences said Pegtarazimod is being evaluated in a Phase 2 trial across 13 U.S. NICUs for newborns with moderate to severe neuroinflammation in HIE. The company said that newborn rats treated with pegtarazimod after oxygen...